TECTONIC THERAPEUTIC, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
TECTONIC THERAPEUTIC, INC. (TECX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $925.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $429.00K, a 18.13% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $496.00K, a 2.94% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $548.00K.
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $535.00K, a 73.70% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $2.12M, a 388.02% increase from fiscal 2024.
- TECTONIC THERAPEUTIC, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $434.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $925.00K 10-Q · filed 2026-08-06 | $1.47M derived: sum of 3 quarters · filed 2026-08-06 | $2.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $496.00K 10-Q · filed 2026-05-07 | $1.04M derived: sum of 2 quarters · filed 2026-05-07 | $1.58M derived: sum of 3 quarters · filed 2026-05-07 | $2.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $548.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.08M derived: sum of 2 quarters · filed 2026-02-26 | $1.61M derived: sum of 3 quarters · filed 2026-08-06 | $2.12M 10-K · filed 2026-02-26 |
| 2025-09-30 | $535.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.06M derived: sum of 2 quarters · filed 2026-08-06 | $1.57M 10-Q · filed 2025-11-06 | $1.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $524.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.03M 10-Q · filed 2026-08-06 | $566.00K derived: sum of 3 quarters · filed 2026-08-06 | $874.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $511.00K 10-Q · filed 2026-05-07 | $42.00K derived: sum of 2 quarters · filed 2026-05-07 | $350.00K derived: sum of 3 quarters · filed 2026-05-07 | $651.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$469.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$161.00K derived: sum of 2 quarters · filed 2026-02-26 | $140.00K derived: sum of 3 quarters · filed 2026-02-26 | $434.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $308.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $609.00K derived: sum of 2 quarters · filed 2025-11-06 | $903.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $595.00K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $294.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |